Aadi bioscience announces financial results for the third quarter of 2022 and provides corporate update

Completed $72.5 million pipe financing extending cash runway into 2025 precision 1 trial on-track with preliminary data expected in the first half of 2023 24% revenue growth of fyarro® (nab-sirolimus) over the second quarter 2022 appointment of neil desai to executive chairman and transition of brendan delaney to ceo effective january 1, 2023 conference call to be held today at 8:30 am et los angeles , nov. 9, 2022 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mtor pathway genes, today provided a corporate update and announced financial results for the third quarter of 2022. "the last several months have been transformational for aadi, most recently having strengthened our balance sheet with a $72.5 million pipe financing.
AADI Ratings Summary
AADI Quant Ranking